Rapid Test Laboratories LLC

Rapid Test Laboratories LLC was paid $9.92M by Medicaid between Oct 2021 and Sep 2024, across 46 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 40% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Arizona

Rank by total paid#6 of 67

Median peer was paid$89K

This provider vs. median111×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2021	461	$21K
2022	60,176	$3.84M
2023	100,533	$5.24M
2024incomplete	26,804	$813K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	40%	40,823	11,476	$3.97M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	27%	29,066	8,221	$2.65M
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	16%	28,468	8,144	$1.58M
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	4.9%	7,186	2,219	$489K
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	4.5%	15,442	5,068	$446K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	3.3%	16,074	4,881	$331K
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	2.1%	17,877	4,915	$213K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	1.1%	3,397	1,292	$113K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	3,679	1,406	$91K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	206	137	$11K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	337	217	$7K
36415	Collection of venous blood by venipuncture	<1%	2,465	858	$3K

34 more codes

G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	55	$3K
83992		<1%	456	$235.41
80361		<1%	501	$155.03
80359		<1%	497	$150.84
80365		<1%	503	$147.96
80306		<1%	19	$119.98
80349		<1%	568	$117.32
80345		<1%	498	$115.08
80348		<1%	532	$113.13
80346		<1%	502	$113.13
80353		<1%	497	$108.94
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	12,540	$102.50
80367		<1%	468	$92.18
80354		<1%	482	$83.80
80356		<1%	464	$75.81
80061	Lipid panel	<1%	62	$74.40
80373		<1%	64	$71.23
80358		<1%	98	$69.87
80357		<1%	466	$66.57
80324		<1%	538	$62.85
80053	Comprehensive metabolic panel	<1%	62	$58.70
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	178	$46.00
80321		<1%	472	$25.14
80377		<1%	32	$3.66
80048	Basic metabolic panel (calcium, ionized)	0%	58	$0.00
H0049	Alcohol and/or drug screening	0%	312	$0.00
99000		0%	66	$0.00
90375		0%	45	$0.00
84478		0%	55	$0.00
83718		0%	60	$0.00
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	0%	16	$0.00
80362		0%	25	$0.00
J9061	Injection, amivantamab-vmjw, 2 mg	0%	1,705	$0.00
82465		0%	58	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBRYANT, WENDY (CEO)

Same official

Other billing entities under BRYANT, WENDY

Full network →

Provider	Location	Paid
Rapid Test Laboratories LLC	Scottsdale, AZ	$91.47

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.